NEW YORK, April 28, 2017 /PRNewswire/ -- Neurotrope,
Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical
company developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease, will issue a press release
announcing results of top-line data from its 148 patient, Phase 2
clinical trial in moderate to severe Alzheimer's Disease, on
Monday May 1, 2017, at
6:30 am, Eastern Time. A
conference call will follow at 8:30 am
Eastern Time on that date.
The dial-in information to access the live call is listed
below:
Participant Toll Free Dial-In
Number: (877)
245-7303
Participant International Dial-In Number:
(478) 219-0731
Conference
ID: 16070779
The dial-in information to access the call replay, available for
30 days after the live call, is listed below:
Replay Toll Free Dial-In
Number: (800)
585-8367
Replay International Dial-In
Number:
(404) 537-3406
Conference
ID: 16070779
Callers should dial in approximately 10 minutes before the live
call begins.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to
treat and potentially reverse moderate to severe Alzheimer's
dementia and other neurodegenerative diseases. The Company's
world-class science is a paradigm shifting approach that treats
some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein
Kinase C isozymes ε and α by Bryostatin-1, a natural product, which
in mouse Alzheimer's disease models was demonstrated to result in
repair of damaged synapses as well as synaptogenesis, the induction
of new neuronal networks, reduction of toxic beta-amyloid
generation, prevention of neuronal death, and enhancement of memory
and learning, thus having the potential to improve cognition and
behavior in Alzheimer's dementia.
Neurotrope has conducted a Phase 2 trial of Bryostatin-1 in the
treatment of moderate to severe Alzheimer's dementia, as well as
preclinical studies of Bryostatin-1 as a treatment for Fragile X
Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare
genetic diseases for which only symptomatic treatments are
currently available. The FDA has granted Orphan Drug Designation to
Neurotrope for Bryostatin-1 as a treatment for Fragile X
Syndrome. Bryostatin-1 has undergone testing in over 1,500
people establishing a large safety database.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. There can be no
assurance that the clinical program for Bryostatin-1 will be
successful in demonstrating safety and/or efficacy, that we will
not encounter problems or delays in clinical development, or that
Bryostatin-1 will ever receive regulatory approval or be
successfully commercialized. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Additional factors that may influence or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased competition,
stock volatility and illiquidity, and the Company's failure to
implement the Company's business plans or strategies. These and
other factors are identified and described in more detail in the
Company's filings with the SEC, including the Company's Annual
Report on Form 10-K for the year ended December 31, 2016. The Company does not undertake
to update these forward-looking statements.
Please visit www.neurotropebioscience.com for further
information.
For additional information, please contact:
Neurotrope Bioscience, Inc.
Jeffrey Benison, Director of Corporate Communications
212.334.8709 or 516.286.6099
jbenison@neurotropebioscience.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurotrope-bioscience-to-release-results-from-phase-2-clinical-trial-in-moderate-to-severe-alzheimers-disease-on-may-1-2017-300447822.html
SOURCE Neurotrope, Inc.